Granulocyte Colony-Stimulating Factor
"Granulocyte Colony-Stimulating Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Descriptor ID |
D016179
|
MeSH Number(s) |
D12.644.276.374.410.240.350 D12.776.395.240.200 D12.776.467.374.410.240.350 D23.529.374.410.240.350
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Granulocyte Colony-Stimulating Factor".
Below are MeSH descriptors whose meaning is more specific than "Granulocyte Colony-Stimulating Factor".
This graph shows the total number of publications written about "Granulocyte Colony-Stimulating Factor" by people in this website by year, and whether "Granulocyte Colony-Stimulating Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 1 | 0 | 1 |
2002 | 0 | 1 | 1 |
2014 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Granulocyte Colony-Stimulating Factor" by people in Profiles.
-
History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol. 2014 Sep; 25(9):1821-9.
-
History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in patients with non-Hodgkin lymphoma not receiving granulocyte colony-stimulating factor prophylaxis. Leuk Lymphoma. 2015 Jan; 56(1):72-9.
-
Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res. 2014 Apr 27; 14:189.
-
Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006 Mar; 40(3):402-7.
-
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002 May; 8(5):500-8.
-
A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis. 2000 Sep; 182(3):970-3.
-
The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project. Am J Clin Oncol. 1994 Oct; 17(5):374-81; discussion 382.